Eledon reports Q3 net loss $10.3M ($0.35/sh); cash $59.6M; advances tegoprubart trials

Eledon Pharmaceuticals, Inc.

2023-Q3 EPS reported -$1.35

Net loss of $10.3M ($0.35 per share) vs $10.5M ($0.73) YoY; R&D spend $7.9M.
Cash & short-term investments $59.6M as of Sept 30, 2023, up from $56.4M at Dec 31, 2022.
Phase 1b data: tegoprubart prevented kidney transplant rejection; mean eGFR >70 at all post-Day 90 timepoints.
First participant dosed in Phase 2 BESTOW trial for kidney transplant rejection; enrollment completion targeted end of 2024.
Tegoprubart used in second-ever pig-to-human heart transplant; appointed new CMO (Eliezer Katz) and two board members.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Eledon Pharmaceuticals, Inc. reported three months ended September 30, 2023 results: net income net loss of $10.3 million, or $0.35 per share, EPS $0.35 per share.

Period: three months ended September 30, 2023
Net income: net loss of $10.3 million, or $0.35 per share
EPS: $0.35 per share
Result: reported results

Exact text from the filing

The company reported a net loss of $10.3 million, or $0.35 per share, for the three months ended September 30, 2023, compared to a net loss of $10.5 million, or $0.73 per share, for the same period in 2022.

View on SEC.gov

Browse all earnings releases →

Eledon Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-062007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.